Status:

COMPLETED

A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers

Lead Sponsor:

Galmed Medical Reserch

Conditions:

Healthy

Eligibility:

MALE

18-50 years

Phase:

PHASE1

Brief Summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1. To assess and characterize the safet...

Detailed Description

Number of Subjects: Total: A total of 46 healthy subjects will be enrolled. Part A: Sixteen (16) subjects will participate in four, 8-person dosing periods. Each cohort will be alternately dosed twic...

Eligibility Criteria

Inclusion

  • Part A: Healthy male volunteers aged 18-50 (inclusive) years who have provided written informed consent
  • Part B: Mildly overweight (25\<BMI \<33), with fasting cholesterol levels of 200-300 mg/% or LDL 100-180 mg/% and triglycerides \< 200 mg/%, otherwise healthy male volunteers aged 18-50 (inclusive) years, who have provided written informed consent
  • Major

Exclusion

  • History of significant neurological (including history of seizures or EEG abnormalities), renal, cardiovascular (including known structural cardiac abnormalities or hypertension), respiratory (asthma), endocrinological, gastrointestinal, hematopoietic disease, neoplasm, psychological (marked anxiety, tension or agitation) or any other clinically significant medical disorder, which in the investigator's judgment contraindicate administration of the study medications.
  • History of drug or alcohol abuse.
  • Known allergy to any drug. Known allergy to any drug.
  • Clinically significant abnormalities found in the screening physical exam.
  • Significant abnormalities in clinical laboratory parameters (hematology, biochemistry, urinalysis) determined within 40 days of the start of the study and on Day (-1) before first dosing session. Parameters to be measured are those shown in Appendix 2.

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2009

Estimated Enrollment :

41 Patients enrolled

Trial Details

Trial ID

NCT00776841

Start Date

September 1 2008

End Date

October 1 2009

Last Update

November 3 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tasmc Clinical Research Center

Tel Aviv, Israel, 64239